Louisiana to receive $6M in EpiPen settlement
BATON ROUGE- Louisiana has joined a multi-state settlement with Mylan Inc. that resolves allegations the drug manufacturer knowingly overcharged taxpayers for EpiPen and EpiPen Jr. dispensed to Medicaid beneficiaries.
The announcement came from Attorney General Jeff Landry’s office.
Mylan will pay $465 million to the federal government and the states, Louisiana’s portion is $6,922,152.05. Landry said the money will go towards replenishing the state’s Medicaid program.
Mylan allegedly submitted false statements to the Centers for Medicare and Medicaid Services that incorrectly classified EpiPen as a “non-innovator multiple source” drug, as opposed to a “single source” or “innovator multiple source” drug from July 29, 2010 to March 31 of this year.
As a result, Mylan submitted or caused false statements to be submitted to CMS and/or the states relating to EpiPen for Medicaid rebate purposes and underpaid its EpiPen rebates to the state Medicaid programs.
Desktop NewsClick to open Continuous News in a sidebar that updates in real-time.
Wingmania: Wings for a good cause
Arraignment expected for 4 involved in LSU hazing-related death
Concerns over construction prompt engineer to assess new downtown library
Drunk driver arrested following crash that killed couple on Florida Boulevard
Concerns over construction prompt large scene at new downtown library